Open AccessAbstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
Author(s) -
Jayesh Desai,
Mark Voskoboynik,
Ben Markman,
Sophia Frentzas,
Paul Foster,
Nageshwar Budha,
Jing Song,
Tarek Meniawy
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.103
H-Index - 449
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct253
Subject(s) - tolerability , medicine , monoclonal antibody , antibody , adverse effect , pharmacokinetics , cancer , oncology , pharmacology , cancer research , immunology